Does TRICARE Cover Enclomiphene Citrate?

Why TRICARE Does Not List Enclomiphene on Its Formulary

TRICARE's Uniform Formulary is managed by the Department of Defense (DoD) Pharmacy and Therapeutics Committee, which evaluates drugs based on FDA approval status, clinical evidence, and cost-effectiveness. Enclomiphene citrate has not received full FDA approval for the treatment of secondary hypogonadism, which is its most common clinical application 1. This off-label status places it outside the standard formulary review pathway.

How the DoD Formulary Process Works

The DoD P&T Committee meets quarterly to review new molecular entities and therapeutic class reviews. Drugs that lack an FDA-approved indication for their primary prescribed use face a higher evidence threshold. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy for men with hypogonadism does not include enclomiphene as a first-line recommendation, partly because the guideline preceded much of the drug's later clinical data.

Enclomiphene vs. Clomiphene: A Formulary Distinction

TRICARE does cover clomiphene citrate (Clomid) for certain fertility indications. Clomiphene is a racemic mixture of two stereoisomers: enclomiphene (trans-clomiphene) and zuclomiphene (cis-clomiphene). Enclomiphene is the pharmacologically active isomer responsible for stimulating gonadotropin release, while zuclomiphene has estrogenic properties that may cause undesirable side effects 2. A 2014 phase III trial (ZA-304, N=253) demonstrated that enclomiphene 25 mg normalized testosterone in 76.4% of men with secondary hypogonadism while maintaining sperm concentrations, compared to topical testosterone gel which suppressed spermatogenesis 3.

This pharmacologic distinction matters for formulary decisions, because TRICARE treats enclomiphene as a separate molecular entity from clomiphene. A prescription for clomiphene citrate will fill at military treatment facility (MTF) pharmacies or through Express Scripts (the TRICARE pharmacy contractor), but a prescription specifying enclomiphene citrate will not 4.

Prior Authorization Requirements for Enclomiphene on TRICARE

TRICARE classifies enclomiphene citrate under its non-formulary prior authorization process. The difficulty level is moderate, meaning approval is possible but requires specific clinical documentation from the prescribing provider.

Documentation Your Provider Must Submit

To obtain prior authorization, a prescriber typically needs to demonstrate:

• A confirmed diagnosis of secondary hypogonadism with two morning serum total testosterone levels below 300 ng/dL, consistent with the Endocrine Society diagnostic criteria [5]
• Medical justification for why standard testosterone replacement therapy (TRT) is contraindicated or inappropriate, such as the patient's desire to preserve fertility 6
• Documentation that clomiphene citrate was trialed or considered, with clinical rationale for preferring the single-isomer formulation
• Relevant lab work including LH, FSH, prolactin, and semen analysis if fertility preservation is the primary indication

Approval Rates and Timelines

TRICARE prior authorization requests are processed through Express Scripts for pharmacy benefits. Standard requests take 5 to 10 business days. Urgent requests can be expedited to 24 to 72 hours. Kim et al. (2016) published data showing enclomiphene citrate significantly increased testosterone, LH, and FSH levels compared to placebo in men with secondary hypogonadism (N=73), evidence that supports medical necessity arguments in PA submissions 7.

A 2021 retrospective study found that off-label clomiphene use for male hypogonadism produced testosterone normalization rates above 70% 8. Providers can cite this body of evidence to strengthen PA requests. TRICARE's pharmacy contractor reviews each case individually, and approval rates vary by region and contractor.

Step Therapy Requirements Under TRICARE

TRICARE may impose step therapy before approving enclomiphene citrate. Step therapy means the plan requires you to try one or more lower-cost or formulary-preferred medications before it will cover an alternative.

Typical Step Therapy Sequence

For secondary hypogonadism, TRICARE's step therapy pathway generally follows this order:

1. Testosterone cypionate injection (formulary-preferred, Tier 1 at MTF pharmacies, ~$30/month through TRICARE)
2. Clomiphene citrate (generic, covered under pharmacy benefit for off-label use with appropriate diagnosis coding) 9
3. Enclomiphene citrate (non-formulary, requires PA after step 1 or step 2 failure or contraindication)

The American Urological Association's 2018 guideline on male infertility recognizes clomiphene citrate as an option for men with hypogonadism who wish to maintain fertility 10. Documenting that the patient tried clomiphene and experienced side effects attributable to the zuclomiphene isomer (visual disturbances, mood changes, gynecomastia) strengthens the case for moving to enclomiphene.

Bypassing Step Therapy

Step therapy can be bypassed if the prescriber documents a clinical contraindication to the preferred agents. For example, a man with a history of polycythemia on testosterone therapy has a legitimate safety reason to avoid exogenous testosterone 11. The Endocrine Society guideline lists hematocrit above 54% as a reason to withhold or discontinue testosterone, making enclomiphene a reasonable alternative in such cases.

Fertility preservation is the strongest clinical argument for bypassing testosterone step therapy entirely. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, reducing intratesticular testosterone and impairing spermatogenesis 12. A 2015 review in Fertility and Sterility confirmed that testosterone-induced azoospermia can take 6 to 12 months to reverse after discontinuation, and recovery is not guaranteed in all men.

How to Appeal a TRICARE Denial of Enclomiphene Citrate

If TRICARE denies your prior authorization request, you have the right to appeal. The process follows a structured pathway through the TRICARE regional contractor.

First-Level Appeal

Submit a written appeal to the TRICARE regional contractor within 90 days of the denial. Include:

• The original denial letter with the specific reason for denial
• A letter of medical necessity from your prescribing physician
• Supporting clinical evidence (the Kim et al. 2016 study 13 and phase III ZA-304 data 14 are commonly cited)
• Updated lab results showing persistent hypogonadism despite step therapy attempts
• Semen analysis if fertility preservation is the basis for the request

Second-Level and ECHO Appeals

If the first appeal is denied, beneficiaries can escalate to the TRICARE Hearing Office. Active-duty service members and their dependents may also explore coverage through the Extended Care Health Option (ECHO) program for qualifying conditions. The Defense Health Agency oversees final appeal decisions, and cases involving fertility preservation in service members have received particular attention given military-specific reproductive health concerns 15.

Tips for a Successful Appeal

Document everything chronologically. Include a timeline showing: diagnosis date, initial treatment attempts, side effects or treatment failures, and the specific clinical rationale for enclomiphene. Appeals that reference published clinical trial data and align with recognized society guidelines have higher success rates than those relying solely on provider preference.

Cost of Enclomiphene Citrate for TRICARE Beneficiaries

Because enclomiphene citrate is not on the TRICARE formulary, out-of-pocket costs depend on how the medication is obtained.

Compounding Pharmacy Pricing

Most enclomiphene citrate prescriptions are filled through compounding pharmacies. Typical prices range from $90 to $150 per month for a 25 mg daily dose. TRICARE does cover certain compounded medications through its pharmacy benefit if the prescription meets specific criteria 16. The compound must be prepared by a pharmacy that meets TRICARE network requirements and follows FDA compounding regulations under section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

Cash-Pay vs. Insurance Routing

For many TRICARE beneficiaries, paying cash at a compounding pharmacy is simpler than navigating the PA and appeal process. A cost comparison:

| Route | Monthly cost | Time to access | |---|---|---| | TRICARE PA (if approved) | $0 to $34 copay | 2 to 6 weeks | | Compounding pharmacy (cash) | $90 to $150 | 3 to 5 days | | Telehealth + compounding | $120 to $200 (includes consult) | 1 to 2 weeks |

Manufacturer Savings Cards and TRICARE

Manufacturer copay assistance programs are generally not usable with federal insurance plans including TRICARE, per the Anti-Kickback Statute and OIG guidance. This restriction applies to TRICARE, CHAMPVA, and all DoD health benefits. Beneficiaries who want to use a savings card would need to decline their TRICARE pharmacy benefit for that specific prescription and pay entirely out of pocket.

Clinical Evidence Supporting Enclomiphene Use

The evidence base for enclomiphene citrate in secondary hypogonadism has grown over the past decade, though the absence of full FDA approval remains a barrier to formulary inclusion.

Key Clinical Trials

The ZA-304 trial (N=253) randomized men with secondary hypogonadism to enclomiphene 12.5 mg, enclomiphene 25 mg, or topical testosterone gel 1%. At 16 weeks, both enclomiphene doses normalized morning testosterone levels while maintaining or improving sperm concentrations 17. Testosterone gel normalized testosterone but significantly suppressed sperm counts, with 29% of gel-treated men dropping below the WHO reference range of 15 million/mL.

A follow-up analysis by Wiehle et al. (2014) confirmed that enclomiphene preserved the HPG axis feedback loop, with LH and FSH levels remaining in the normal range throughout treatment 18. This preservation of endogenous hormone signaling is the pharmacologic basis for fertility maintenance during treatment.

Safety Profile

Reported adverse effects in clinical trials include headache (8.2%), hot flashes (4.1%), and nausea (3.6%) 19. Visual disturbances, which occur in 5% to 7% of patients taking racemic clomiphene, were reported in fewer than 2% of enclomiphene-treated subjects, likely because the zuclomiphene isomer is primarily responsible for ocular side effects 20.

Long-Term Data Gaps

No published trial has followed enclomiphene-treated men beyond 12 months. The FDA's 2015 advisory on testosterone products [21] raised concerns about cardiovascular risk with exogenous testosterone, which indirectly supports interest in alternatives like enclomiphene. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that testosterone replacement did not increase the incidence of major adverse cardiovascular events compared to placebo over a mean follow-up of 33 months 22. Whether enclomiphene carries similar or different cardiovascular risk remains unstudied in a dedicated outcomes trial.

Special Considerations for Active-Duty Service Members

Active-duty personnel receive pharmacy benefits exclusively through MTF pharmacies at no cost or through TRICARE's mail-order pharmacy. Enclomiphene's absence from the Uniform Formulary means it will not be stocked at any MTF.

Fertility Preservation in Deploying Service Members

The DoD has expanded fertility preservation benefits in recent years, including coverage for sperm and oocyte cryopreservation for service members facing deployment to combat zones 23. This policy reflects recognition that military service poses unique reproductive risks. A service member diagnosed with secondary hypogonadism who needs both testosterone normalization and fertility maintenance has a compelling case for enclomiphene coverage through the PA pathway.

Referral to Endocrinology

TRICARE Prime requires referrals for specialty care. A referral to endocrinology or reproductive urology strengthens an enclomiphene PA request because the prescribing specialist can document the clinical rationale more thoroughly. The American Society for Reproductive Medicine (ASRM) position statement on hormonal management of male factor infertility supports the use of selective estrogen receptor modulators (SERMs) as an alternative to exogenous testosterone when fertility is a concern [24].

Alternatives Covered by TRICARE

If enclomiphene is denied and the appeal is unsuccessful, several alternatives remain accessible through TRICARE.

Clomiphene Citrate (Generic Clomid)

Clomiphene citrate 25 to 50 mg daily is widely prescribed off-label for male hypogonadism and is covered under TRICARE's pharmacy benefit. A 2019 meta-analysis found that clomiphene increased total testosterone by an average of 292 ng/dL (95% CI: 215 to 369) across 15 studies 25. The trade-off is a higher rate of estrogenic side effects from the zuclomiphene component.

Anastrozole

The aromatase inhibitor anastrozole (0.5 to 1 mg daily or every other day) is sometimes used off-label to raise testosterone-to-estradiol ratios in men with obesity-related hypogonadism. It is available as a generic and covered under TRICARE, though evidence for this indication is limited to small studies 26.

hCG (Human Chorionic Gonadotropin)

HCG mimics LH and directly stimulates testicular testosterone production while preserving spermatogenesis. TRICARE covers FDA-approved hCG products. Dosing typically ranges from 1,500 to 3,000 IU two to three times weekly 27. The injectable route and higher cost compared to oral enclomiphene are practical disadvantages.